Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression | PHASE1 | RECRUITING | 84 | — | — | Jan 9, 2026 | Feb 15, 2029 | May 19, 2026 | 30 | United States, Australia +7 |
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed. Adverse events will be defined as treatment-emergent if they have an onset or worsen (by investigator report of a change in intensity) during the study treatment or the safety follow-up period but prior to any subsequent cancer therapy.
| Arm | Type | Description |
|---|---|---|
| Module 1: AZD3632 dose 1 | EXPERIMENTAL | Participants will receive AZD3632 (dose 1) through the treatment period. |
| Module 1: AZD3632 dose 2 | EXPERIMENTAL | Participants will receive AZD3632 (dose 2) through the treatment period. |
| Module 1: AZD3632 dose 3 | EXPERIMENTAL | Participants will receive AZD3632 (dose 3) through the treatment period. |
| Module 1: AZD3632 dose 4 | EXPERIMENTAL | Participants will receive AZD3632 (dose 4) through the treatment period. |
| Module 1: AZD3632 dose 5 | EXPERIMENTAL | Participants will receive AZD3632 (dose 5) through the treatment period. |
| Module 1: AZD3632 dose 6 | EXPERIMENTAL | Participants will receive AZD3632 (dose 6) through the treatment period. |
| Module 2: AZD3632 + posaconazole | EXPERIMENTAL | Participants will receive AZD3632 alone, then will receive AZD3632 in combination with posaconazole through treatment period. |
| Name | Type | Description |
|---|---|---|
| AZD3632 | DRUG | AZD3632 will be administered orally. |
| Posaconazole | DRUG | Posaconazole will be administered orally. |
Key Inclusion Criteria: Core criteria: * Adequate organ function. * Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Module 1: * Advanced haematologic malignan...